Breast Cancer Trials
Select Clinical Trial
Protocol Number: NRG-BR003
Protocol Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Eligibility: Men or women ages 18 and older, diagnosed with HER2 negative triple-negative invasive breast cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: AFT-38
Protocol Title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Eligibility: Men or women ages 18 and older, diagnosed with HER2 positive, hormone receptor positive, metastatic or unresectable breast cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: NSABP B-59
Protocol Title: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Eligibility: Men or women ages 18 and older, diagnosed with triple-negative invasive breast cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Alliance A011502/ABC Trial/Breast
Protocol Title: Studies how well Aspirin works in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
Eligibility: Patient population: 18 to 70 years of age; women or men with node positive, HER2 negative after chemotherapy, surgery, and/or radiation therapy; enrolled within 1 year after diagnosis;No known allergy to aspirin
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: TULIP / SYD985.002
Protocol Title: A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Eligibility: Women ages 18 or older and have had previous treatment with HER2 targeting regimes
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1418
Protocol Title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Eligibility: Women ages 18 and older, diagnosis of breast cancer with negative estrogen (ER)- and progesterone-receptor (PR) status, and negative (HER)2 receptor, with disease following therapy before surgery.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: NRG-BR004
Protocol Title: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in first-line HER2-Positive Metastatic Breast Cancer
Eligibility: Men or women, ages 18 and older, diagnosed with HER2 positive adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Sanofi ACT16105
Protocol Title: An open-label randomized Phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies.
Eligibility: Patients ≥18 years of age with a proven diagnosis of adenocarcinoma of the breast and evidence of either locally advanced, not amenable to radiation therapy or surgery in a curative intent, and/or metastatic disease.
Contact Information: (910) 715-2200